{
    "clinical_study": {
        "@rank": "40081", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: normal liver function", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Cohort 2: severe liver dysfunction", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, Phase I study will evaluate the impact of severe hepatic impairment on the\n      pharmacokinetics and safety of vemurafenib in patients with BRAF V600 mutation positive\n      cancer. Patients will receive vemurafenib 960 mg (normal hepatic function) or 720 mg (severe\n      hepatic impairment) orally twice daily on Days 1 to 20 (morning dose) and from Day 27\n      onwards until disease progression or inacceptable toxicity occurs."
        }, 
        "brief_title": "A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Histologically confirmed BRAF V600 mutation-positive advanced solid malignancy that\n             is metastatic or unresectable and for which standard curative or palliative measures\n             do not exist or are no longer effective\n\n          -  Normal or impaired hepatic function (hepatic function will be classified according to\n             the NCI Organ Dysfunction Working Group criteria)\n\n          -  For patients with hepatic impairment: Stable hepatic function for at least 2 weeks\n             before Day 1\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of </=2\n\n          -  Patients with a history of recent brain metastases must have completed any radiation\n             therapy at least 4 weeks before Day 1, be without intervening signs of brain lesion\n             progression and not require steroids before starting the protocol (Day 1). Patients\n             with gliomas or known brain metastases who require anticonvulsants must be seizure\n             free for 1 month prior to enrollment\n\n          -  Life expectancy > 8 weeks\n\n          -  Adequate hematologic and renal function\n\n          -  Females patients of childbearing potential and male patients with female partners of\n             childbearing potential must agree to use two adequate methods of contraception as\n             defined by protocol during the course of this study and for at least 6 months after\n             completion of study treatment\n\n        Exclusion Criteria:\n\n          -  Allergy or hypersensitivity to components of the vemurafenib formulation\n\n          -  Requirement for immediate or urgent treatment with vemurafenib and for whom the\n             intermittent schedule of vemurafenib employed during Days 1-26 in this trial is not\n             clinically acceptable\n\n          -  Chemotherapy, biologic therapy, immunotherapy, or radiotherapy within 4 weeks prior\n             to entering the study, or those who have not recovered from AEs because of agents\n             administered more than 4 weeks earlier\n\n          -  Gliomas or known brain metastases that require corticosteroids\n\n          -  History of clinically significant cardiac or pulmonary dysfunction\n\n          -  HIV-positive patient requiring antiviral treatment including protease inhibitors\n\n          -  Active infection or chronic infection requiring chronic suppressive antibiotics\n\n          -  Pregnancy or breastfeeding at Day 1\n\n          -  History of malabsorption or other clinically significant metabolic dysfunction\n\n          -  Active autoimmune disease\n\n          -  Current, recent (within 28 days prior to Day 1), or planned use of any\n             investigational product outside this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767623", 
            "org_study_id": "GO28053", 
            "secondary_id": "2012-003820-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1: normal liver function", 
                "description": "960 mg BID", 
                "intervention_name": "vemurafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2: severe liver dysfunction", 
                "description": "720 mg BID", 
                "intervention_name": "vemurafenib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Encinitas", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92008"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankston", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3199"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11527"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "31096"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel", 
                        "zip": "6423906"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arequipa", 
                        "country": "Peru", 
                        "zip": "51 54"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru", 
                        "zip": "34"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krasnodar", 
                        "country": "Russian Federation", 
                        "zip": "350040"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izmir", 
                        "country": "Turkey", 
                        "zip": "35100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cardiff", 
                        "country": "United Kingdom", 
                        "zip": "CF14 2TL"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Greece", 
                "Israel", 
                "Peru", 
                "Russian Federation", 
                "Turkey", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO28053 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Dose-normalized area under the concentration-time curve (AUC) during the dose interval on Day 20 (steady state)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 168 hours after the morning dose Day 20"
            }, 
            {
                "measure": "Dose-normalized maximum concentration (Cmax) on Day 20 (steady state)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 168 hours after the morning dose on Day 20"
            }
        ], 
        "removed_countries": {
            "country": "Argentina"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767623"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Dose-normalized AUC on Day 1", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Dose-normalized AUC on Day 20", 
                "safety_issue": "No", 
                "time_frame": "Day 20"
            }, 
            {
                "measure": "Dose-normalized Cmax on Day 1", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Time to maximum concentration (tmax) on Day 1 and 20", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 20"
            }, 
            {
                "measure": "Half-life (t1/2) in plasma on Day 20", 
                "safety_issue": "No", 
                "time_frame": "Day 20"
            }, 
            {
                "measure": "Dose-normalized clearance (CL/F) on Day 20", 
                "safety_issue": "No", 
                "time_frame": "Day 20"
            }, 
            {
                "measure": "Trough plasma concentration (Cmin or Ctrough)", 
                "safety_issue": "No", 
                "time_frame": "up to Day 20"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}